Bisphosphonates inhibit bone resorption in vivo and in vitro by unknown mechanisms. The effect of bisphosphonates on the formation of osteoclasts from their mononuclear hematopoietic precursors was investigated using human long-term marrow cultures in which multinucleated cells form that express most of the known features of the osteoclast phenotype (e.g., bone resorption, tartrate-resistant acid phosphatase, calcitonin responsiveness, and reactivity with specific MAbs). The five bisphosphonates that were tested strongly inhibited 1,25-dihydroxyvitamin D3-stimulated formation of these cells with the same relative pqtencies as they inhibit ione resorption in vivo. Two representative compounds (3-amino-1-hydroxypropylidene-1,1-bisphosphonate and dichloromethylene bisphosphonate) failed to inhibit the proliferation of precursors of the osteoclast-like cells. However, these compounds decreased the proportion of mononuclear and multinucleated cells expressing an osteoclast antigen, thus suggesting a degree of specificity for cells of the osteoclast lineage. We conclude that bisphosphonates are potent inhibitors of osteoclast-like cell formation in long-term human mprrow cultures, #nd that this may be related to their ability to inhibit bone resorption in vivo.
Introduction
The stable pyrophosphate analogues known as bisphosphonates (PCPs,1 also designated diphosphonates) are potent inhibitors of bone resorption in vivo and in vitro (reviewed by Fleisch in reference 1) and are established therapeutic agents in Paget's disease ofbone (I1-7) and hypercalcemia ofmalignancy (8) (9) (10) ). The precise mechanism of action of these compounds is not understood. It was originally thought that PCPs might inhibit bone resorption through physicochemical effects on hydroxyapatite dissolution (1 1). More recently it has become clear that PCPs have a wide variety of effects on cells thought to be involved in bone turnover, such as osteoblasts (12, 13) and cells belonging to the mononuclear phagocyte system (14) (15) (16) . However, the relative potencies with which different PCPs inhibit crystal dissolution or cause most of their cellular effects in vitro differ from the relative potencies of these compounds in experimental animals or as therapeutic agents in man. There is some evidence to suggest that PCPs may inhibit the recruitment or differentiation of the osteoclast precursor (17) , which is thought to be a mononuclear cell of hematopoietic origin (18) (19) (20) . We have investigated the effects of PCPs on the formation of multinucleated cells (MNC) in human long-term marrow cultures (described by MacDonald et al., reference 21). Many of the cells formed in these cultures display a number of phenotypic characteristics normally associated with osteoclasts. We have studied the effects of five PCPs on the formation of these cells stimulated by 1,25-dihydroxyvitamin D3 (1,25 D) and colony-stimulating factors, and on the expression of an antigen expressed by osteoclasts but not by cells of the mononuclear phagocyte system.
Methods
Long-term human marrow culture. Human marrow was obtained from sections of rib removed during thoracotomy. The mononuclear fraction was separated by density gradient centrifugation through FicollHypaque (Sigma, Poole, Dorset, UK). These cells were washed and resuspended in MEM-alpha (Gibco, Paisley, Renfrewshire, UK) plus 20% heat-inactivated horse serum (Gibco). The cells were then added to 16- (22, 23) . In the latter experiments, the cells were incubated with 10% GCT-CM, 10 nM 1,25 D, or no stimulus dunng the first week of culture, and 10 nM 1,25 D during the second and third weeks. PCPs were made up as 10-mM solutions in PBS (Gibco); the pH was adjusted to 7;4 where necessary and further dilutions were made in culture medium. Unless otherwise mentioned, the PCPs were present during the entire culture period. The following compounds were tested: 3-amino-I-hydroxypropylidene-l,l-bisphosphonate (AHPrBP, formerly APD), dichloromethylene bisphosphonate (Cl2MBP, formerly Cl2MDP), 1-hydroxethylidene-l,l-bisphosphonate (HEBP, formerly EHDP), 6-amino-l-hydroxyhexylidene-l,l-bisphosphonate (AHHexBP, formerly AHDP), and 3-pyridyl-I-hydroxyethylidene-1, 1-bisphosphonate (3-PHEBP). 
Results
All of the five compounds tested inhibited MNC formation stimulated by 10 nM 1,25D in a dose-dependent manner at concentrations between l0-' and 10-4 M (Fig. 1) . Using an extended concentration range of l0-10l0-4 M, IC50 values were estimated. The data shown in Table I show that although (32) . Given that five compounds could have 120 different orders of potency, the probability of the same order occurring by chance in three experiments is 1 in 1203 or 6 X IO-'. The inhibition of MNC formation shown in these experiments may therefore be the major action of PCPs in vivo.
The inhibitory effect of AHPrBP and C12MBP on the expression by MNC of the antigen recognized by 13 C2 suggests that PCPs inhibit the formation of osteoclast-like MNC more strongly than they inhibit the formation of non-osteoclast-like MNC. Although 13 C2 also reacts with renal proximal tubule cells and glomerular viscera, it can be considered as osteoclast-specific in the context ofbone marrow cultures, as it does not react with other hematopoietic cells (24) . This MAb also inhibits the resorption of devitalized bone by isolated osteoclasts (33), thus suggesting that it binds to an important functional site on the osteoclast. The identity of the mononuclear cells that react with 13 C2 is uncertain, but as neither monocytes nor bone marrow-derived macrophages react with this antibody, these cells are probably closely related to the osteoclast, possibly being precursors. Fuller and Chambers (34) have shown that when cultures of rabbit bone marrow are grown on devitalized bone, the presence of resorption pits detected by scanning electron microscopy correlates with the presence of mononuclear cells or cells of low multinuclearity reacting with another anti-osteoclast monoclonal (23 C6) been demonstrated both in the marrow culture system described here (21) and on bone surfaces in vivo immediately before the appearance of osteoclasts in the bone remodeling sequence (36) . These observations support the concept that the osteoclast precursor may express features ofthe osteoclast phenotype during the later stages of its differentiation, and that such cells may be present in long-term marrow cultures. Furthermore, recent studies suggest that the protein with which 13 C2 reacts is a receptor for a matrix protein (35) . It is generally believed that mononuclear osteoclast precursors attach themselves to the bone surface before fusing (36) Transforming growth factor-alpha and epidermal growth factor stimulate the formation of MNC in these cultures through enhanced precursor proliferation (30) . Granulocytemacrophage colony-stimulating factor and macrophage colony-stimulating factor, both ofwhich are present in GCT-CM, have also been shown to have this effect in long-term cultures of baboon marrow (37) . Neither AHPrBP nor C12MBP significantly inhibited GCT-CM-stimulated precursor proliferation during the first week of culture. This might appear to contradict the findings of Cecchini et al. (38) who observed that three PCPs, including AHPrBP and C12MBP, inhibited granulocytemacrophage and macrophage colony-stimulating factor-stimulated colony formation in murine marrow cultures. However, these effects may be overcome in long-term cultures, and probably do not occur to a significant extent in vivo, as suppression of myelopoiesis has very rarely been reported in PCP-treated patients. Studies by Boonekamp et al. (17, 39 ) using organ culture systems have suggested that PCPs have two modes of action on osteoclastic bone resorption, inhibiting both the accession (migration to the bone surface and fusion) ofosteoclast precursors and resorption by the mature osteoclast. Higher concentrations (10-M and above) were required to inhibit resorption by preformed osteoclasts than were required to inhibit accession of osteoclast precursors (10-6 M and above, in the case of AHPrBP). The relative potencies of the three compounds tested in these systems (AHPrBP, C12MBP, and HEBP) also differed; C12MBP inhibited resorption by mature osteoclasts most strongly, whereas the relative potencies of these three compounds in inhibiting osteoclast precursor accession were the same as those seen in our studies. It would therefore appear that although they are capable of acting directly on adult osteoclasts, PCPs inhibit bone resorption primarily by an effect on the formation ofosteoclasts that appears to be at the level of the postmitotic precursor.
Long-term marrow culture may, therefore, prove to be a useful ex vivo technique for studying the efficacy of new therapeutic agents and the mechanism of action of existing ones. Bisphosphonates are potentially the most efficacious therapeutic agents for treating diseases of increased bone turnover such as Paget's disease and many cases of hypercalcemia of malignancy. Furthermore, PCPs may prove to have applications in other diseases of bone and mineral metabolism such as hyperparathyroidism (7) and certain forms of osteoporosis (40) . It has been shown in a single case that bone marrow taken from a patient with hyperparathyroidism formed MNC in greater numbers than normal controls and that this effect was reversed after parathyroidectomy (21). The ability to study MNC formation in disease states illustrates the usefulness ofthis system for the study of the pathophysiological and pharmacological control of bone resorption. Unfortunately, the first PCP available for general use, etidronate (HEBP), causes mineralization defects during long-term administration (3, 41) and therefore should in time be replaced by more potent compounds (such as AHPrBP, C12MBP, or AHHexBP) that lack this side effect at therapeutic doses. Other new, highly potent PCPs, for example 3-PHEBP, are currently being studied. Long-term marrow cultures may prove to be a valuable screening technique for these compounds.
